<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with coincidental <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> (RA) treated by allogeneic hematopoietic stem cell transplantation (HSCT) for drug induced <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> have been fortuitously cured of RA </plain></SENT>
<SENT sid="1" pm="."><plain>Other than these examples with allogeneic HSCT, there is no known curative therapy for RA </plain></SENT>
<SENT sid="2" pm="."><plain>Despite its potential to cure, allogeneic transplantation is not being offered to patients with RA due to transplant related mortality </plain></SENT>
<SENT sid="3" pm="."><plain>Advances in HSCT conditioning regimens and better prevention of <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> should allow consideration of allogeneic HSCT as therapy for severe RA </plain></SENT>
<SENT sid="4" pm="."><plain>We propose a new, well tolerated, nonmyeloablative allogeneic stem cell transplant regimen as treatment for RA </plain></SENT>
</text></document>